<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00159575</url>
  </required_header>
  <id_info>
    <org_study_id>MET-AR study -PCOS 5</org_study_id>
    <secondary_id>EUDRACTNR. 2004-001124-20</secondary_id>
    <nct_id>NCT00159575</nct_id>
  </id_info>
  <brief_title>Metformin in Assisted Reproduction-MET-AR-study</brief_title>
  <official_title>Metformin Treatment Before IVF / ICSI in Non-obese Women With Polycystic Ovarian Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of study: To investigate whether four months of metformin treatment before IVF&#xD;
      (in-vitro-fertilisation) or ICSI (intra-cytoplasmic-sperm-injection) might increase clinical&#xD;
      pregnancy rate in normal-weight (body mass index [BMI] below 28 kg/m3) in PCOS (polycystic&#xD;
      ovarian syndrome) women.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PCOS is an hormonal disease including hyperandrogenism, oligo-or anovulation and/or&#xD;
      polycystic ovaries by ultrasound. PCOS women often suffer insulin resistance or even diabetes&#xD;
      risk as well as a full blown metabolic disease.&#xD;
&#xD;
      These women often suffer infertility due to their lack of regular ovulations. Metformin is a&#xD;
      well known anti-diabetic drug, and in some PCOS women metformin might decrease the&#xD;
      hyperandrogenism, improve insulin resistance and give more regular ovulations. Thereby&#xD;
      increase chance of pregnancy. Our hypothesis is that metformin will increase clinical&#xD;
      pregnancy rates both spontaneously and following IVF/ICSI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow patient recruitment and expiry of study medication(aug2009)&#xD;
  </why_stopped>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate whether four months of Metformin treatment before IVF (in-vitro-fertilisation) or ICSI (intra-cytoplasmic sperm injection) will increase clinical pregnancy rate in normal weight PCOS-women</measure>
    <time_frame>Vaginal ultrasound in pregnancy week 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spontaneous pregnancy rates during the pretreatment period, Spontaneous abortion rates (I or II trim.abortions), Live birth rates,</measure>
    <time_frame>Vaginal ultrasound in pregnancy week 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oocytes collected, Embryo quality, Number of days of gonadotrophin treatment, Dose of gonadotrophin, total per cycle and daily, s-estradiol on day of hCG-administration, Occurrence of ovarian hyperstimulation syndrome (OHSS)</measure>
    <time_frame>All data evaluated at study end, from september 2009 onwards</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>M: Metformin P: Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin / Placebo treatment for 4 months</intervention_name>
    <description>M: Metformin 2000mg daily- 12-14 weeks of pretreatment + metformin 2000mg daily through conventional IVF ending on the day of pregnancy test; IE. 14 days after embryo transfer. P: Or identical placebo treatment for the same period</description>
    <arm_group_label>M: Metformin P: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fulfilling Rotterdam criteria for PCOS&#xD;
&#xD;
          -  Infertility more than 1 year&#xD;
&#xD;
          -  First or second cycle of IVF/ICSI treatment&#xD;
&#xD;
          -  Age below 38 years at inclusion&#xD;
&#xD;
          -  BMI below 28 kg/m3 at inclusion&#xD;
&#xD;
          -  Willing to be randomised to 4 months metformin or placebo&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not suitable for starting dose 112.5 IE&#xD;
&#xD;
          -  Basal FSH above 10 IU/L&#xD;
&#xD;
          -  Known renal disease or s-creatinine above 110 umol/L&#xD;
&#xD;
          -  Known liver disease or s-ALAT above 80 IU/L&#xD;
&#xD;
          -  Known alcoholism or drug abuse&#xD;
&#xD;
          -  Known diabetes mellitus or fasting plasma glucose above 7 mmol/L&#xD;
&#xD;
          -  Corticosteroid treatment (oral)&#xD;
&#xD;
          -  Treatment with cimetidine, anticoagulants, erythromycin or other macrolides&#xD;
&#xD;
          -  Hyperprolactinemia (PRL above 700 mIU/L)&#xD;
&#xD;
          -  Abnormal thyroid function tests&#xD;
&#xD;
          -  Known congenital adrenal hyperplasia&#xD;
&#xD;
          -  Androgen secreting tumours&#xD;
&#xD;
          -  Cushing syndrome&#xD;
&#xD;
          -  Metformin treatment within the last one month prior to screening&#xD;
&#xD;
          -  Unfit to participate for any other reason&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>38 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sven Carlsen, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>St Olavs Hospital- Endocrinological section</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sigrun Kjøtrød</name>
      <address>
        <city>Trondheim</city>
        <zip>7006</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertility UNit- -St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <zip>7046</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Kjøtrød SB, Carlsen SM, Rasmussen PE, Holst-Larsen T, Mellembakken J, Thurin-Kjellberg A, Haapaniemikouru K, Morin-Papunen L, Humaidan P, Sunde A, von Düring V. Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. Hum Reprod. 2011 Aug;26(8):2045-53. doi: 10.1093/humrep/der154. Epub 2011 May 23.</citation>
    <PMID>21606131</PMID>
  </results_reference>
  <verification_date>January 2012</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>January 2, 2012</last_update_submitted>
  <last_update_submitted_qc>January 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Polycystic ovarian syndrome</keyword>
  <keyword>Clinical pregnancy rate</keyword>
  <keyword>Oligo- or anovulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

